Contribution of celiac disease autoantibodies to the disease process

References

• Lindfors K, Mäki M, Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools? Autoimmun. Rev.9(11), 744–749 (2010).
   PubMed Web of Science ®Google Scholar
• Korponay-Szabó IR, Sulkanen S, Halttunen T et al. Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies. J. Pediatr. Gastroenterol. Nut.31(5), 520–527 (2000).
   PubMed Web of Science ®Google Scholar
• Belkin AM. Extracellular TG2: emerging functions and regulation. FEBS J.278(24), 4704–4716 (2011).
   PubMed Web of Science ®Google Scholar
• Akimov SS, Krylov D, Fleischman LF, Belkin AM. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell Biol.148(4), 825–838 (2000).
   PubMed Web of Science ®Google Scholar
• Telci D, Wang Z, Li X et al. Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and β1 integrin co-signaling. J. Biol. Chem.283(30), 20937–20947 (2008).
   PubMed Web of Science ®Google Scholar
• Koskinen O, Collin P, Lindfors K, Laurila K, Mäki M, Kaukinen K. Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. J. Clin. Gastroenterol.44(7), 483–488 (2010).
   PubMed Web of Science ®Google Scholar
• Teesalu K, Panarina M, Uibo O, Uibo R, Utt M. Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial cell adhesion. Amino Acids doi:10.1007/s00726-011-1020-1021-1 (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Myrsky E, Kaukinen K, Syrjänen M, Korponay-Szabó IR, Mäki M, Lindfors K. Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin. Exp. Immunol.152(1), 111–119 (2008).
   PubMed Web of Science ®Google Scholar
• Myrsky E, Caja S, Simon-Vecsei Z et al. Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. Cell. Mol. Life Sci.66(20), 3375–3385 (2009).
   PubMed Web of Science ®Google Scholar
• Caputo I, Barone MV, Lepretti M et al. Celiac anti-tissue transglutaminase antibodies interfere with the uptake of α gliadin peptide 31–43 but not of peptide 57–68 by epithelial cells. Biochim. Biophys. Acta1802(9), 717–727 (2010).
   PubMed Web of Science ®Google Scholar
• Halttunen T, Mäki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology116(3), 566–572 (1999).
   PubMed Web of Science ®Google Scholar
• Barone MV, Caputo I, Ribecco MT et al. Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology132(4), 1245–1253 (2007).
   PubMed Web of Science ®Google Scholar
• Zanoni G, Navone R, Lunardi C et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med.3(9), e358 (2006).
   PubMed Web of Science ®Google Scholar
• Rauhavirta T, Qiao SW, Jiang Z et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin. Exp. Immunol.164(1), 127–136 (2011).
   PubMed Web of Science ®Google Scholar
• Verderio EA, Telci D, Okoye A, Melino G, Griffin M. A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J. Biol. Chem.278(43), 42604–42614 (2003).
   PubMed Web of Science ®Google Scholar
• Király R, Vecsei Z, Deményi T, Korponay-Szabó IR, Fésüs L. Coeliac autoantibodies can enhance transamidating and inhibit GTPase activity of tissue transglutaminase: dependence on reaction environment and enzyme fitness. J. Autoimmun.26(4), 278–287 (2006).
   PubMed Web of Science ®Google Scholar
• Caja S, Myrsky E, Korponay-Szabo IR et al. Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies. Scand. J. Gastroenterol.45(4), 421–427 (2010).
   PubMed Web of Science ®Google Scholar
• Esposito C, Paparo F, Caputo I et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut51(2), 177–181 (2002).
   PubMed Web of Science ®Google Scholar
• Dieterich W, Trapp D, Esslinger B et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut52(11), 1562–1566 (2003).
   PubMed Web of Science ®Google Scholar
• Kainulainen H, Rantala I, Collin P et al. Blisters in small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase-2. Gut50(1), 81–89 (2002).
   Google Scholar